Understanding Cellectis' Share Capital and Voting Rights
Cellectis, a pioneer in the field of gene editing, provides regular updates regarding its share capital and voting rights to keep investors and stakeholders informed of its financial health and governance structure.
Key Financial Information
The company operates within the Euronext Growth market, highlighting its dynamic participation in the European financial landscape. The ISIN code corresponding to Cellectis is FR0010425595, which is essential for investors looking to identify and track the company's shares effectively.
Recent Share Capital Update
As of the end of a recent reporting period, Cellectis registered a total of 100,093,873 shares in its capital. This figure is pivotal, showcasing the company's asset base and providing a basis for calculating ownership stakes and shareholder influence. This total reflects a healthy level of capital that can be utilized to promote the company's innovative projects.
Voting Rights Overview
The total number of voting rights associated with these shares is recorded at 88,660,539. This number indicates the influence that shareholders have in guiding company decisions, particularly at annual general meetings. The discrepancy between total shares and voting rights can often arise from various factors, including share classes and company policy regarding voting.
Engaging with Cellectis
For those interested in learning more about Cellectis or seeking additional data, the company provides direct lines of communication through its investor relations and media contacts. Engaging with the company not only informs investors but also fosters a community of stakeholders passionate about advancements in gene editing.
Media Inquiries
Pascalyne Wilson, Director of Communications, is available for media-related queries. Contact can be established at +33 (0)7 76 99 14 33. For direct media correspondence, you can reach out via email.
Investor Relations Contact
For prospective and current investors, Arthur Stril, the Interim Chief Financial Officer, can be contacted at +1 (347) 809 5980. The investor relations team is dedicated to ensuring that financial stakeholders are kept up-to-date with ongoing developments within the organization.
Commitment to Transparency
Cellectis demonstrates a strong commitment to transparency and communication with its shareholders and the broader community. Frequent updates on share capital and voting rights form an integral part of this commitment, ensuring that stakeholders can make informed decisions based on accurate and current information.
Frequently Asked Questions
What is the total number of shares in Cellectis' capital?
The total number of shares in Cellectis' capital is 100,093,873.
How many voting rights are associated with Cellectis shares?
Cellectis has a total of 88,660,539 voting rights linked to its shares.
Where is Cellectis listed?
Cellectis is listed on the Euronext Growth market, indicating its active participation in European capital markets.
Who can I contact for media inquiries about Cellectis?
For media inquiries, please reach out to Pascalyne Wilson, Director of Communications, at +33 (0)7 76 99 14 33.
How can investors stay informed about Cellectis?
Investors can stay informed about Cellectis by reaching out to Arthur Stril, the Interim Chief Financial Officer, at +1 (347) 809 5980 for the latest updates and announcements.
